LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Clinical trial NCT01271725 · COMPLETED

Trial details

NCT number: NCT01271725
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2011-05-24
Primary completion: 2017-03-13
Enrollment: 74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.